<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04001998</url>
  </required_header>
  <id_info>
    <org_study_id>B-2660-102</org_study_id>
    <nct_id>NCT04001998</nct_id>
  </id_info>
  <brief_title>Healthy Volunteer Study Comparing Tablet and Capsule Formulations</brief_title>
  <official_title>A Two-Part, Open Label, Complete Crossover Study to Compare the Tablet and Capsule Formulations of BLD-2660, Including a Food Effect Assessment of the Tablet Formulation, and to Assess Dose Proportionality Following Single Oral Doses of BLD-2660 in Tablet Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blade Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blade Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, randomized, open label, two-part crossover study designed to evaluate the PK,
      food effect, dose proportionality, safety, and tolerability of BLD-2660 in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the drug concentration-time curve from time zero to the last measurable concentration (AUC0-last)</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Measured by plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to infinity (AUC0-inf)</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Measured by plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed drug concentration (Cmax)</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Measured by plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of the maximum drug concentration (Tmax)</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Measured by plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal half-life (t½)</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Measured by plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination rate constant (Kel)</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Measured by plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>AEs will be assessed by determining the incidence, severity, and dose relationship of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>Tablet vs Capsule Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of BLD-2660 capsule or tablet formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Proportionality</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of BLD-2660 tablet formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLD-2660</intervention_name>
    <description>Randomized to active product</description>
    <arm_group_label>Dose Proportionality</arm_group_label>
    <arm_group_label>Tablet vs Capsule Formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide written informed consent

          -  Agree to no smoking or alcohol or illegal substance 48 hours prior to dosing

          -  Normal BMI (18 to ≤ 35 kg/m2)

          -  Have a negative urine drug screen/alcohol breath test on admission to clinic

          -  Agree to use highly effective, double barrier contraception (both male and female
             partners) during the study and for 90 days following completion of dosing

          -  Females of childbearing potential must have a negative serum pregnancy test at
             Screening and a negative urine or serum pregnancy test on Day -1

          -  Be in general good health

          -  Clinical laboratory values within normal range

        Exclusion Criteria:

          -  Recent wound, or presence of an ongoing non-healing skin wound

          -  Presence of any underlying physical or psychological medical condition that, in the
             opinion of the Investigator, would make it unlikely that the subject will complete the
             study per protocol

          -  History or presence of alcoholism or drug abuse within the 2 years prior to the first
             study drug administration, and unwillingness to be totally abstinent during the dosing
             period

          -  Blood donation or significant blood loss within 30 days prior to the first study drug
             administration

          -  Plasma donation within 7 days prior to the first study drug administration

          -  Administration of investigational product (IP) in another trial within 30 days prior
             to the first study drug administration, or five half-lives, whichever is longer

          -  Females who are pregnant or lactating

          -  Surgery within the past 3 months prior to the first study drug administration
             determined by the PI to be clinically relevant

          -  Failure to satisfy the PI of fitness to participate for any other reason

          -  Active infection or history of recurrent infections

          -  Active malignancy and history of malignancy in the past 2 years, with the exception of
             completely excised basal cell carcinoma or low grade cervical intraepithelial
             neoplasia

          -  Antibiotic treatment within 3 months

          -  Chronic medical condition

          -  Any acute illness within 30 days prior

        Other protocol defined inclusion/exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Lemech, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientia Clinical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina Baccei</last_name>
    <phone>650-443-7366</phone>
    <email>cbaccei@blademed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scientia Clinical Research</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>June 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>August 1, 2019</last_update_submitted>
  <last_update_submitted_qc>August 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

